Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Longboard Pharmaceuticals, Inc. (LBPH) is a clinical-stage biopharmaceutical company pioneering novel therapies for rare neurological disorders. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments, research breakthroughs, and regulatory progress.
Access authoritative information on LBPH's innovative pipeline, including program-specific updates across their portfolio of optimized neurological therapeutics. The resource consolidates official press releases, clinical trial milestones, and strategic partnership announcements in one centralized location.
Key content categories include updates on drug candidate development, regulatory filings, scientific presentations, and corporate governance matters. All materials maintain factual accuracy while avoiding speculative commentary to support informed decision-making.
Bookmark this page for streamlined access to verified LBPH developments. Check regularly for updates on their mission to advance transformative treatments for complex neurological conditions through precision pharmacology.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced participation in five upcoming epilepsy-focused events, enhancing community engagement. Leadership highlights include sharing insights on the Phase 1b/2a PACIFIC Study for LP352, targeting seizures in developmental and epileptic encephalopathies. The events include the Epilepsy Foundation Pipeline Conference on June 5-6, the LGSF International Conference on June 17-19, the DSF Conference on June 23-25, and others in July. LP352 is a novel treatment aimed at improving seizure control and developmental delays associated with various severe epileptic disorders.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced participation in the Citi Movement Disorder & Epilepsy Co-Panel on May 18, 2022, at 3:30 PM ET. This event is exclusive to registered attendees. Additionally, Longboard will present at the H.C. Wainwright Global Investment Hybrid Conference from May 23-26, 2022, with a webcast available on May 24 at 7:00 AM ET. Archived presentations will be accessible for 30 days on the company’s website. Longboard focuses on developing innovative medicines for neurological diseases, including LP352 for seizure treatment and LP659 for multiple neurological disorders.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced progress in its clinical studies and financial results for Q1 2022. The Phase 1b/2a PACIFIC Study for LP352, targeting severe epilepsies, is ongoing, with initial data presented at the AAN Annual Meeting in April. The company reported a cash position of approximately $96.1 million, projected to support operations into 2024. However, R&D expenses rose by 62% to $7.1 million, contributing to a net loss of $9.6 million, or $0.56 per share, compared to the same period last year.
Longboard Pharmaceuticals (Nasdaq: LBPH) has announced the presentation of Phase 1 data for LP352 at the upcoming American Academy of Neurology Annual Meeting. The trial results demonstrate favorable safety, tolerability, and pharmacokinetics in healthy volunteers. LP352, a selective 5-HT2c receptor superagonist, aims to treat seizures associated with developmental and epileptic encephalopathies. The company is eager to advance to the Phase 1b/2a PACIFIC Study involving patients with severe epilepsy.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced participation in the Cantor Fitzgerald’s Rare Orphan Disease Summit on March 30, 2022. The senior leadership team will join the Rare and General Epilepsy and Seizure Disorders panel at 2:45 PM ET. The presentation is exclusive to registered attendees, who can contact Cantor Fitzgerald for details. Longboard focuses on developing innovative therapies for neurological diseases, including LP352 for seizures related to developmental and epileptic encephalopathies, LP659 for various neurological conditions, and LP143 targeting central nervous system disorders.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced that President & CEO Kevin Lind will present at the Maxim Group LLC Virtual Growth Conference from March 28-30, 2022. Participants can access the presentation via M-Vest starting March 28 at 9:00 AM ET until March 30 at 5:00 PM ET, with registration required. An archived webcast will be available afterward on Longboard's website, ensuring availability for at least 30 days. This conference features executives from diverse sectors, offering opportunities for investor engagement through presentations and Q&A sessions.
Longboard Pharmaceuticals (Nasdaq: LBPH) announces the retirement of Dr. Philip Perera as Chief Medical Officer, while he will remain as an advisor. Dr. Randall Kaye has been appointed as the new CMO. Dr. Perera's leadership contributed to the success of the Phase 1 MAD study of LP352 and initiated clinical trials for developmental and epileptic encephalopathies. Dr. Kaye brings over 30 years of experience in clinical development within CNS therapeutic areas. The company aims to advance its neurology-focused pipeline under his guidance.
Longboard Pharmaceuticals (Nasdaq: LBPH) has initiated the Phase 1b/2a PACIFIC Study to evaluate LP352 in patients with developmental and epileptic encephalopathies (DEEs). The study aims to enroll about 50 participants and is expected to conclude in the second half of 2023. In preclinical studies, LP352 showed an 85% reduction in epileptiform event frequency. The company reported a cash position of approximately $106.7 million, sufficient to fund operations into 2024. For 2021, Longboard recorded a net loss of $27.8 million, equating to $1.93 per share.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced its participation in the H.C. Wainwright BioConnect Virtual Conference, scheduled for January 10, 2022, commencing at 7:00 AM ET. The presentation will be accessible via the Events & Presentations page on Longboard's Investor Relations website. Longboard specializes in developing innovative treatments for neurological disorders, focusing on G protein-coupled receptors. The company is advancing several product candidates, including LP352 for seizures and LP143 for neurodegenerative diseases. The presentation will be archived for 30 days post-event.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced the appointment of Dr. Jane Tiller to its board of directors on November 17, 2021. Dr. Tiller brings extensive experience in neuroscience and clinical development. Previously, she served as Chief Medical Officer at Neumora Therapeutics and held key roles at Bristol-Myers Squibb, including Vice President of Global Medical for neuroscience. This addition aims to strengthen Longboard's leadership as the company advances its pipeline of innovative medicines for neurological diseases.
